Literature DB >> 2866388

(+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism.

A J Stoessl, E Mak, D B Calne.   

Abstract

PHNO is a naphthoxazine compound with selective D2 agonist properties and a molecular structure unrelated to the morphine and ergot derivatives that have been used to treat Parkinson's disease. A double-blind, dose-ranging study on 8 patients showed that it is effective in the treatment of parkinsonism; its duration of effect of up to 6 h could make it useful for patients who experience wearing-off reactions with levodopa.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2866388     DOI： 10.1016/s0140-6736(85)92627-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  6 in total

1.  (+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.

Authors:  N M Rupniak; S Boyce; M J Steventon; S D Iversen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

2.  Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  C E Clarke; S Boyce; M A Sambrook; S M Stahl; A R Crossman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

3.  Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

Authors:  S Boyce; N M Rupniak; M J Steventon; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.

Authors:  C M Gust; S K Hemrick-Luecke; R W Fuller
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

5.  Binding of (+)PHNO and other D2-dopamine agonists to D1-dopamine receptors labelled by [3H]SCH 23390.

Authors:  D J Pettibone; J A Totaro; B V Clineschmidt
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

6.  The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.

Authors:  W J Weiner; S A Factor; J R Sanchez-Ramos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.